NERx Biosciences to Present New Data Highlighting Their Pre-clinical Pipeline of Drugs Targeting the DNA Damage Response at American Association For Cancer Research Annual Meeting in April
The new drugs target the DNA Damage Response (DDR) pathway, allowing doctors to selectively kill cancer cells.
- The new drugs target the DNA Damage Response (DDR) pathway, allowing doctors to selectively kill cancer cells.
- The two first-in-class drugs will be presented by NERx Biosciences at the American Association for Cancer Research (AACR) 2022 Annual Meeting , being held April 8-13, 2022, in New Orleans, LA.
- In vivo targeting Replication Protein A for cancer therapy, will be presented on April 11 in the Genomic instability I (9 am - 12:30 pm) session.
- The novel targets and drugs under development at NERx are on the forefront and hold considerable potential to change the treatment of cancer.